S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
New AI Stock Payouts (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
New AI Stock Payouts (Ad)
3 Stocks That Flourish In The Fall
2 Must-Have Silicon Companies That Don't Make Microchips
New AI Stock Payouts (Ad)
Buy The World’s Largest IT Infrastructure Provider For Under $20
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
New AI Stock Payouts (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
New AI Stock Payouts (Ad)
3 Stocks That Flourish In The Fall
2 Must-Have Silicon Companies That Don't Make Microchips
New AI Stock Payouts (Ad)
Buy The World’s Largest IT Infrastructure Provider For Under $20
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
New AI Stock Payouts (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
New AI Stock Payouts (Ad)
3 Stocks That Flourish In The Fall
2 Must-Have Silicon Companies That Don't Make Microchips
New AI Stock Payouts (Ad)
Buy The World’s Largest IT Infrastructure Provider For Under $20
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
New AI Stock Payouts (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
New AI Stock Payouts (Ad)
3 Stocks That Flourish In The Fall
2 Must-Have Silicon Companies That Don't Make Microchips
New AI Stock Payouts (Ad)
Buy The World’s Largest IT Infrastructure Provider For Under $20
Small Caps That Have Priced In A Hard Landing For Big Upside
NYSE:RMD

ResMed (RMD) Stock Forecast, Price & News

$138.28
+1.67 (+1.22%)
(As of 09/25/2023 ET)
Compare
Today's Range
$136.26
$138.41
50-Day Range
$136.29
$225.35
52-Week Range
$136.20
$243.52
Volume
1.84 million shs
Average Volume
1.70 million shs
Market Capitalization
$20.34 billion
P/E Ratio
22.67
Dividend Yield
1.39%
Price Target
$248.29

ResMed MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
79.6% Upside
$248.29 Price Target
Short Interest
Healthy
2.15% of Shares Sold Short
Dividend Strength
Moderate
Based on Four Factors
Sustainability
-0.56
Upright™ Environmental Score
News Sentiment
0.59mentions of ResMed in the last 14 days
Based on 13 Articles This Week
Insider Trading
Selling Shares
$3.85 M Sold Last Quarter
Proj. Earnings Growth
12.23%
From $7.03 to $7.89 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.33 out of 5 stars

Medical Sector

6th out of 962 stocks

Surgical & Medical Instruments Industry

1st out of 95 stocks


RMD stock logo

About ResMed (NYSE:RMD) Stock

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. The company was founded in 1989 and is headquartered in San Diego, California.

RMD Price History

RMD Stock News Headlines

AI stock's 1,029% month!
In January, AI could have produced three top winners during the month...And $1,000 in each of the three trades would've turned into $30,886! How is this possible? Using a new strategy called "One Ticker Payouts".  Click here to see all the details and proof for yourself.
ResMed (NYSE:RMD) Reaches New 52-Week Low Following Insider Selling
ResMed (NYSE:RMD) Price Target Cut to $230.00
Here's The Price I'll Buy ResMed Stock
AI stock's 1,029% month!
In January, AI could have produced three top winners during the month...And $1,000 in each of the three trades would've turned into $30,886! How is this possible? Using a new strategy called "One Ticker Payouts".  Click here to see all the details and proof for yourself.
ResMed Unusual Options Activity For September 15
ResMed - Trading Opportunity Now
Looking At ResMed's Recent Unusual Options Activity
UBS Downgrades Resmed (RMD)
ResMed Announces Participation in Upcoming Conferences
ResMed hits 52-week low after Q4 miss
See More Headlines
Receive RMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ResMed and its competitors with MarketBeat's FREE daily newsletter.

RMD Company Calendar

Last Earnings
8/03/2023
Ex-Dividend for 9/21 Dividend
8/16/2023
Dividend Payable
9/21/2023
Today
9/26/2023
Next Earnings (Estimated)
10/26/2023
Fiscal Year End
6/30/2024

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
CUSIP
76115210
Employees
10,140
Year Founded
1989

Price Target and Rating

Average Stock Price Forecast
$248.29
High Stock Price Forecast
$290.00
Low Stock Price Forecast
$180.00
Forecasted Upside/Downside
+79.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
10 Analysts

Profitability

Net Income
$897.56 million
Pretax Margin
26.09%

Debt

Sales & Book Value

Annual Sales
$4.22 billion
Cash Flow
$7.90 per share
Book Value
$28.11 per share

Miscellaneous

Free Float
145,027,000
Market Cap
$20.34 billion
Optionable
Optionable
Beta
0.52

Social Links

5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Michael J. Farrell BEMr. Michael J. Farrell BE (Age 51)
    MBA, SM, CEO & Chairman
    Comp: $2.66M
  • Mr. Robert A. DouglasMr. Robert A. Douglas (Age 63)
    Pres & COO
    Comp: $1.82M
  • Dr. Peter C. Farrell A.M. (Age 81)
    AM, B.E., BE (Hons), Ph.D., ScD, Founder, Chair Emeritus & Director
    Comp: $430.56k
  • Mr. Brett A. SandercockMr. Brett A. Sandercock (Age 56)
    Chief Financial Officer
    Comp: $891.39k
  • Mr. David B. PendarvisMr. David B. Pendarvis (Age 64)
    Consultant
    Comp: $1.11M
  • Mr. Kaushik  GhoshalMr. Kaushik Ghoshal (Age 54)
    Pres of SaaS Bus.
    Comp: $1.11M
  • Ms. Urvashi Tyagi
    Chief Technology Officer
  • Ms. Amy Wakeham
    Chief Communications & Investor Relations Officer
  • Mr. Michael J. RiderMr. Michael J. Rider (Age 65)
    Global Gen. Counsel & Sec.
  • Ms. Vered Keisar
    Chief People Officer













RMD Stock - Frequently Asked Questions

Should I buy or sell ResMed stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ResMed in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RMD shares.
View RMD analyst ratings
or view top-rated stocks.

What is ResMed's stock price forecast for 2023?

10 Wall Street research analysts have issued twelve-month target prices for ResMed's shares. Their RMD share price forecasts range from $180.00 to $290.00. On average, they anticipate the company's stock price to reach $248.29 in the next year. This suggests a possible upside of 79.6% from the stock's current price.
View analysts price targets for RMD
or view top-rated stocks among Wall Street analysts.

How have RMD shares performed in 2023?

ResMed's stock was trading at $208.13 on January 1st, 2023. Since then, RMD stock has decreased by 33.6% and is now trading at $138.28.
View the best growth stocks for 2023 here
.

Are investors shorting ResMed?

ResMed saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 3,160,000 shares, an increase of 110.7% from the August 15th total of 1,500,000 shares. Based on an average daily trading volume, of 1,130,000 shares, the short-interest ratio is presently 2.8 days.
View ResMed's Short Interest
.

When is ResMed's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 26th 2023.
View our RMD earnings forecast
.

How were ResMed's earnings last quarter?

ResMed Inc. (NYSE:RMD) posted its earnings results on Thursday, August, 3rd. The medical equipment provider reported $1.60 earnings per share for the quarter, missing the consensus estimate of $1.67 by $0.07. The medical equipment provider had revenue of $1.12 billion for the quarter, compared to analyst estimates of $1.14 billion. ResMed had a net margin of 21.25% and a trailing twelve-month return on equity of 24.94%. The firm's revenue was up 22.7% on a year-over-year basis. During the same period in the previous year, the firm earned $1.49 earnings per share.
Read the conference call transcript
.

How often does ResMed pay dividends? What is the dividend yield for ResMed?

ResMed declared a quarterly dividend on Thursday, August 3rd. Investors of record on Thursday, August 17th will be paid a dividend of $0.48 per share on Thursday, September 21st. This represents a $1.92 annualized dividend and a yield of 1.39%. The ex-dividend date is Wednesday, August 16th. This is an increase from the stock's previous quarterly dividend of $0.44.
Read our dividend analysis for RMD
.

Is ResMed a good dividend stock?

ResMed (NYSE:RMD) pays an annual dividend of $1.92 per share and currently has a dividend yield of 1.41%. The company has been increasing its dividend for 3 consecutive year(s), indicating that it does not yet have a strong track record of dividend growth. The dividend payout ratio is 31.48%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, RMD will have a dividend payout ratio of 24.33% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for RMD.

What is Mick Farrell's approval rating as ResMed's CEO?

284 employees have rated ResMed Chief Executive Officer Mick Farrell on Glassdoor.com. Mick Farrell has an approval rating of 92% among the company's employees. This puts Mick Farrell in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ResMed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ResMed investors own include NVIDIA (NVDA), Walt Disney (DIS), Intel (INTC), AbbVie (ABBV), Netflix (NFLX), Adobe (ADBE), Visa (V), Alibaba Group (BABA), PayPal (PYPL) and QUALCOMM (QCOM).

What is ResMed's stock symbol?

ResMed trades on the New York Stock Exchange (NYSE) under the ticker symbol "RMD."

Who are ResMed's major shareholders?

ResMed's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.33%), State Street Corp (4.35%), WCM Investment Management LLC (2.39%), Geode Capital Management LLC (2.27%), Capital World Investors (1.60%) and Northern Trust Corp (1.10%). Insiders that own company stock include Brett Sandercock, Carol Burt, Dave Michaud, David Pendarvis, James Hollingshead, Justin Leong, Karen Drexler, Kaushik Ghoshal, Lucile Blaise, Michael J Farrell, Michael J Rider, Peter C Farrell, Rajwant Sodhi, Robert Andrew Douglas and Ronald R Taylor.
View institutional ownership trends
.

How do I buy shares of ResMed?

Shares of RMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ResMed's stock price today?

One share of RMD stock can currently be purchased for approximately $138.28.

How much money does ResMed make?

ResMed (NYSE:RMD) has a market capitalization of $20.34 billion and generates $4.22 billion in revenue each year. The medical equipment provider earns $897.56 million in net income (profit) each year or $6.10 on an earnings per share basis.

How many employees does ResMed have?

The company employs 10,140 workers across the globe.

Does ResMed have any subsidiaries?
The following companies are subsidiares of ResMed: Matrixcare, and Propeller Health.
Read More
How can I contact ResMed?

ResMed's mailing address is 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA, 92123. The official website for the company is www.resmed.com. The medical equipment provider can be reached via phone at (858) 836-5000, via email at investorrelations@resmed.com, or via fax at 858-836-5501.

This page (NYSE:RMD) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -